Blog Big Molecule Watch November 23, 2021

Innovent Announces Results of Phase III Trial of Sintilimab and Bevacizumab Combination Therapy In Patients With Advanced Lung Cancer

Innovent Biologics, Inc. announced the results of the Phase III ORIENT-31 study evaluating sintilimab in combination with BYVASDA (bevacizumab biosimilar) for the treatment of non-squamous non-small cell lung cancer.  According to the press release, patients receiving sintilimab plus BYVASDA combined with chemotherapy (pemetrexed and cisplatin) demonstrated an improvement in progression-free survival compared with patients receiving chemotherapy alone.  The median progression-free survival was 6.9 months for the sintilimab-and-BYVASDA patients as compared with 4.3 months for the chemotherapy-only patients.

Sintilimab is a PD-1 inhibitor that is marketed as TYVYT in China, where it is approved to treat relapsed or refractory classic Hodgkin’s lymphoma after two lines or later of systemic chemotherapy, as first-line treatment of nonsquamous non-small cell lung cancer when given in combination with pemetrexed and platinum chemotherapy, as first-line treatment of squamous non-small cell lung cancer when given in combination with gemcitabine and platinum chemotherapy, and as first-line treatment of hepatocellular carcinoma when given in combination with BYVASDA.

This past May, the FDA accepted for review a BLA for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of nonsquamous non-small cell lung cancer.

The post Innovent Announces Results of Phase III Trial of Sintilimab and Bevacizumab Combination Therapy In Patients With Advanced Lung Cancer appeared first on Big Molecule Watch.